<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035278</url>
  </required_header>
  <id_info>
    <org_study_id>Dengusiil-01</org_study_id>
    <nct_id>NCT04035278</nct_id>
  </id_info>
  <brief_title>A Phase 1 Safety Study of Dengusiil in Healthy Adults</brief_title>
  <official_title>A Phase 1, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Dengusiil in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serum Institute of India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD Australia Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Serum Institute of India Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to assess safety and tolerability of a single subcutaneous dose of&#xD;
      Dengusiil in healthy adults of 18 to 45 years of age. In this study, immune response to&#xD;
      Dengusiil will also be assessed over a period of 6 months and vaccine viremia will also be&#xD;
      assessed over a period of 12 days after administration of vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited local and systemic reactions</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, severity, and relatedness to vaccination of unsolicited adverse events</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, severity, and relatedness to vaccination of serious adverse events</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with clinically significant abnormal safety laboratory (hematology and chemistry parameters) findings</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with clinically significant physical examination and vital signs findings</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with seroconversion for DENV-1 to 4 virus neutralization antibodies (PRNT50) titer</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants seropositive for DENV-1 to 4 virus neutralizing antibodies</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants seropositive for DENV-1 to 4 virus neutralizing antibodies</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) of DENV-1 to 4 virus neutralization antibodies</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of DENV-1 to 4 virus neutralization antibodies</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with viremia for each of DENV-1 to 4</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prevention of Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Dengusiil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dengusiil</intervention_name>
    <description>Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.</description>
    <arm_group_label>Dengusiil</arm_group_label>
    <other_name>Live attenuated tetravalent vaccine containing all four dengue virus serotypes (DENV1, 2, 3 and 4)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lyophilized powder containing all the components of the vaccine except DENV serotypes 1, 2, 3 and 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults aged 18-45, men, or women.&#xD;
&#xD;
          2. Seronegative for Dengue NS1 and IgM at screening indicating no current dengue&#xD;
             infection&#xD;
&#xD;
          3. Seronegative for dengue IgG at screening&#xD;
&#xD;
          4. Participants who are willing to comply with the requirements of the study protocol and&#xD;
             attend scheduled visits.&#xD;
&#xD;
          5. Participants who give written informed consent approved by the Human Research Ethics&#xD;
             Committee (HREC) governing the site.&#xD;
&#xD;
          6. Participants must have the laboratory parameters within normal range.&#xD;
&#xD;
          7. Participants with Body Mass Index (BMI) between 18 to 30 (both inclusive)&#xD;
&#xD;
          8. Satisfactory baseline medical assessment as assessed by physical examination and&#xD;
             normal laboratory values or minor variations those are acceptable for study entry.&#xD;
&#xD;
          9. Participants should agree to not:&#xD;
&#xD;
               1. donate blood for the purpose of blood transfusion&#xD;
&#xD;
               2. donate an organ for the purpose of transplantation&#xD;
&#xD;
               3. to share needles with other people&#xD;
&#xD;
               4. allow their blood to come in contact with another person's mucous membranes for&#xD;
                  84 days post-vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous dengue vaccination.&#xD;
&#xD;
          2. Presence of acute infection in the preceding 14 days or presence of a temperature ≥&#xD;
             38.0°C, or acute symptoms of infection greater than of &quot;mild&quot; severity on the&#xD;
             scheduled date of first dosing&#xD;
&#xD;
          3. Evidence of any other significant active haematological disease, or having donated &gt;&#xD;
             450 mL of blood within the past three months.&#xD;
&#xD;
          4. Evidence or history of substance abuse including alcohol or previous substance abuse&#xD;
             within the last year.&#xD;
&#xD;
          5. Participation or planned participation in a study involving the administration of an&#xD;
             investigational compound within the past one month or during this study period.&#xD;
&#xD;
          6. Planned administration of any vaccine not foreseen by the study protocol 4 weeks&#xD;
             before and after dosing.&#xD;
&#xD;
          7. History of allergic disease, allergic reactions or known hypersensitivity to any&#xD;
             component of the study vaccines.&#xD;
&#xD;
          8. Confirmed or suspected immunosuppressive or immune-deficient condition.&#xD;
&#xD;
          9. A family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
         10. Chronic administration (defined as more than 14 days) of immune-suppressants or other&#xD;
             immune-modifying agents within six months prior to administration of study vaccine.&#xD;
             (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day; topical&#xD;
             or inhalable steroids are allowed.)&#xD;
&#xD;
         11. Laboratory confirmed infection with either hepatitis B virus (HBs Ag positive),&#xD;
             hepatitis C virus (anti-HCV positive), or human immunodeficiency virus (HIV) at&#xD;
             screening.&#xD;
&#xD;
         12. Known bleeding disorders.&#xD;
&#xD;
         13. Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the administration of study vaccines or planned administration during the&#xD;
             study period.&#xD;
&#xD;
         14. Women who are pregnant, breast-feeding, or considering becoming pregnant.&#xD;
&#xD;
         15. Any other condition, which in the opinion of the investigator, might interfere with&#xD;
             the study objectives, jeopardize the safety or rights of the participant or making it&#xD;
             unlikely the participant could complete the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PRASAD KULKARNI, MD</last_name>
    <role>Study Director</role>
    <affiliation>SERUM INSTITUTE OF INDIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

